Proton pump inhibitor concomitant use to prevent oxaliplatin‐induced peripheral neuropathy: Clinical retrospective cohort study
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy2025Vol. 45(7), pp. 435–447
Citations Over TimeTop 10% of 2025 papers
Keisuke Mine, Takehiro Kawashiri, Kohei Mori, Yusuke Mori, Haruna Ishida, Hibiki Kudamatsu, Shunsuke Fujita, Mayako Uchida, Takaaki Yamada, Nobuaki Egashira, Ichiro Ieiri, Satoru Koyanagi, Shigehiro Ohdo, Takao Shimazoe, Daisuke Kobayashi
Abstract
These results suggest that concomitant PPI use may reduce oxaliplatin discontinuation due to OIPN in patients receiving oxaliplatin.
Related Papers
- → In Vitro Chemosensitivity Test for Gastric Cancer Specimens Predicts Effectiveness of Oxaliplatin and 5-Fluorouracil(2017)7 cited
- → Clinical Features of Oxaliplatin-induced Hypersensitivity Reactions in Chinese Patients: A Retrospective Multicenter Analysis(2021)5 cited
- mFOLFOX6/Bevacizumabによる治療開始後に脾臓が増大しOxaliplatin休薬により脾臓が縮小した大腸癌の2 例(2011)
- Oxaliplatin─Based Chemotherapy の腹膜播種を伴うStage IV 大腸癌に対する効果(2013)
- → 03:00 PM Abstract No. 316 Morphology, loadability, and releasing profiles of CalliSpheres microspheres in delivering oxaliplatin: an in vitro study(2019)